Cardio Diagnostics Holdings (NASDAQ: CDIO) is making a direct push into the employer benefits market, participating in four national benefits conferences in June to discuss innovative approaches to cardiovascular disease prevention and cost management. The company’s engagement comes as cardiovascular disease remains one of the most expensive health conditions in the United States, accounting for approximately 11% of all U.S. healthcare expenditures in 2020–2021—more than any major diagnostic category, according to the American Heart Association.
“A single heart attack or major cardiovascular event can have consequences that extend far beyond a patient’s health, affecting employers, insurers and healthcare systems through higher medical costs, lost productivity and long-term care expenses,” the company noted in a press release. As organizations responsible for employee benefits seek new strategies to address rising healthcare spending, Cardio Diagnostics is positioning its suite of solutions to provide earlier identification of cardiovascular risk and enable more targeted interventions and preventive care.
The conferences provide a platform for the company to engage directly with benefits managers, human resources professionals and other stakeholders who are increasingly focused on managing the financial and human toll of chronic disease. By leveraging its proprietary diagnostics, Cardio Diagnostics aims to help employers identify employees at risk before a cardiac event occurs, potentially reducing costly emergency care, hospitalizations and long-term disability claims.
The company’s participation underscores a broader trend in employer-sponsored healthcare: a shift from reactive treatment to proactive prevention. With cardiovascular disease driving a significant share of healthcare spending, even modest improvements in early detection and management could yield substantial savings for self-insured employers and health plans. Cardio Diagnostics’ technology offers a scalable way to screen large employee populations without requiring extensive clinical infrastructure.
Forward-looking statements in the company’s announcement caution that actual results may differ materially from projections. Detailed risk factors are available in Cardio Diagnostics’ filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and subsequent quarterly reports. For the latest news and updates relating to CDIO, visit the company’s newsroom at https://ibn.fm/CDIO. Full terms of use and disclaimers are available on the InvestorBrandNetwork website at http://IBN.fm/Disclaimer.
